Generic competition · all medicines · read 12 November 2026

Is there a generic of Valsartan, and who makes it?

Valsartan appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 18 generic makers listed as marketed across them. Where both are dated, the first generic approval came between 3.9 and 12.9 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Method designed and maintained by Vincent Wesley Couey (ORCID 0009-0005-6869-308X). Data compiled automatically from the Orange Book data files, downloaded 12 November 2026. How these pages are made

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Valsartan3 dosage-form groups in the Orange Book
18generic makers listed
  1. Valsartan appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 18 generic makers listed as marketed across them.
  2. Where both are dated, the first generic approval came between 3.9 and 12.9 years after the first brand approval.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Diovan. 16 generic makers with 64 generic products listed as marketed; the first generic approval is dated 26 June 2014.

2000200520102015202020252030016brand 2001Ohm Laboratories Inc, first approval 26 June 2014Alembic Pharmaceuticals Ltd, first approval 5 January 2015Aurobindo Pharma Ltd, first approval 5 January 2015Hetero Labs Ltd Unit V, first approval 5 January 2015Jubilant Generics Ltd, first approval 5 January 2015Mylan Pharmaceuticals Inc, first approval 5 January 2015Prinston Pharmaceutical Inc, first approval 9 June 2015Amneal Pharmaceuticals Of New York Llc, first approval 11 January 2016Macleods Pharmaceuticals Ltd, first approval 16 September 2016Adaptis Pharma Private Ltd, first approval 9 April 2018Alkem Laboratories Ltd, first approval 12 March 2019Dr Reddys Laboratories Ltd, first approval 5 October 2021Sciegen Pharmaceuticals Inc, first approval 27 October 2021Zydus Lifesciences Ltd, first approval 22 July 2024Pharmobedient Consulting Llc, first approval 21 April 2026Bostal Drug Delivery Co Ltd, first approval 11 August 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Ohm Laboratories Inc26 June 20144
Alembic Pharmaceuticals Ltd5 January 20154
Aurobindo Pharma Ltd5 January 20154
Hetero Labs Ltd Unit V5 January 20154
Jubilant Generics Ltd5 January 20154
Mylan Pharmaceuticals Inc5 January 20154
Prinston Pharmaceutical Inc9 June 20154
Amneal Pharmaceuticals Of New York Llc11 January 20164
Macleods Pharmaceuticals Ltd16 September 20164
Adaptis Pharma Private Ltd9 April 20184
Alkem Laboratories Ltd12 March 20194
Dr Reddys Laboratories Ltd5 October 20214

4 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Oral

One to three generic makers listed

Brand listed as marketed: Prexxartan. 2 generic makers with 2 generic products listed as marketed; the first generic approval is dated 2 November 2021.

201520202025203002brand 2017Novitium Pharma Llc, first approval 2 November 2021Rubicon Research Ltd, first approval 5 June 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Novitium Pharma Llc2 November 20211
Rubicon Research Ltd5 June 20251

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Capsule, Oral

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

1995200020052010201520202025203001brand 1996data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

What do pharmacies pay for Valsartan?

The CMS NADAC survey tracks what pharmacies pay to acquire Valsartan: 4 products with year-end prices from 2014 to 2026. See the acquisition cost history on RxGrab. It is a pharmacy cost, not a retail price, and this page does not say how it relates to the number of makers listed above.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.